The reduction below 5% removes the requirement for future 13G filings by Invus, but the passive nature and small decrease suggest no strategic shift. Monitor for any further selling ahead of the Merck KGaA acquisition close in Q1 2027.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $19.80entry
- T+1 · 4d ago +0.15%α +0.51% · $19.83
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Invus Global Management and affiliated entities filed an amended Schedule 13G disclosing a 4.6% aggregate beneficial ownership stake in Silence Therapeutics plc as of September 30, 2026, down from a prior 5.2% stake. The filing confirms a passive investment intent with no activist purpose.
Key Financial Metrics
Key Facts
- Invus entities hold 8,663,601 ordinary shares (4.6% of 186,609,072 shares outstanding as of October 15, 2026)
- Stake decreased from 5.2% in prior filing (October 13, 2026) to 4.6%
- Invus Public Equities holds 7,591,233 shares (4.1%), Avicenna Fund holds 1,072,368 shares (0.6%)
- Filing confirms passive investment under Rule 13d-1(c) with no control intent
- Filing coincides with Silence Therapeutics' pending acquisition by Merck KGaA, expected to close Q1 2027
Financial Impact
Stake reduction from ~5.2% to 4.6% represents a decrease of approximately 0.6 percentage points of beneficial ownership
Risk Factors
- Stake reduction could signal reduced conviction ahead of the pending acquisition
- No material financial impact expected given the small size of the decrease
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0002005369-26-000060 |
| Document: 0002005369-26-000060-index.html | 0002005369-26-000060 |
| Document: 0002005369-26-000060.txt | 0002005369-26-000060 |
Track record
15 reports on SLN
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Viewing Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers